Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 127 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016', provides in depth analysis on Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) 
- The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Overview 10
Therapeutics Development 11
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Stage of Development 11
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Therapy Area 12
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Indication 13
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Companies 18
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Products under Development by Universities/Institutes 24
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment 26
Assessment by Monotherapy/Combination Products 26
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development 33
Advaxis, Inc. 33
American Gene Technologies International Inc. 34
Aprea AB 35
Cellceutix Corporation 36
Critical Outcome Technologies Inc. 37
Eleos Inc. 38
ORCA Therapeutics B.V. 39
OSE Immunotherapeutics 40
PCI Biotech Holding ASA 41
Quark Pharmaceuticals, Inc. 42
Shenzen SiBiono GeneTech Co., Ltd. 43
SK Biopharmaceuticals Co., Ltd. 44
Stemline Therapeutics, Inc. 45
Tara Immuno-Oncology Therapeutics LLC 46
Z53 Therapeutics, LLC 47
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles 48
Adxs-LmddA159 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AG-1101 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
APR-017 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
APR-246 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ATRN-502 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
cenersen sodium - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
contusugene ladenovec - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
COTI-2 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
D-12PGJ3 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Gene Therapy to Activate p53 for Oncology - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
KM-3174 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
MHY-449 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MJ-05 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
MX-225 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
N-2 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Oncolytic Viruses to Activate p53 for Oncology - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
OSE-2101 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
p28 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
QPAL-1 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
QPI-1002 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Recombinant Protein to Activate p53 for Oncology - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
SGT-53 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
SL-801 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Small Molecules to Activate p53 for Melanoma - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Small Molecules to Activate p53 for Oncology - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
ZMC-1 - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Projects 107
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products 114
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Featured News & Press Releases 115
Aug 03, 2016: Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data 115
Jul 12, 2016: Critical Outcome Initiates Third Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers 116
Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study 116
Jun 06, 2016: Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53 117
Jun 06, 2016: Aprea AB Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with Investigational APR-246 Presented at 2016 ASCO Annual Meeting 118
Jun 06, 2016: Cancer drug trial success 119
May 24, 2016: Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment 120
May 03, 2016: Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1 Trial 120
Apr 27, 2016: Critical Outcome Technologies Augments Advisory Board Drug Development Experience 120
Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers 121
Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer 122
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002 123
Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients 123
Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer 124
Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers 125
Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 126
Disclaimer 127

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 (Contd..2) 21
Products under Development by Companies, H2 2016 (Contd..3) 22
Products under Development by Companies, H2 2016 (Contd..4) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Products under Investigation by Universities/Institutes, H2 2016 25
Assessment by Monotherapy/Combination Products, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Pipeline by Advaxis, Inc., H2 2016 33
Pipeline by American Gene Technologies International Inc., H2 2016 34
Pipeline by Aprea AB, H2 2016 35
Pipeline by Cellceutix Corporation, H2 2016 36
Pipeline by Critical Outcome Technologies Inc., H2 2016 37
Pipeline by Eleos Inc., H2 2016 38
Pipeline by ORCA Therapeutics B.V., H2 2016 39
Pipeline by OSE Immunotherapeutics, H2 2016 40
Pipeline by PCI Biotech Holding ASA, H2 2016 41
Pipeline by Quark Pharmaceuticals, Inc., H2 2016 42
Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 43
Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 44
Pipeline by Stemline Therapeutics, Inc., H2 2016 45
Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 46
Pipeline by Z53 Therapeutics, LLC, H2 2016 47
Dormant Projects, H2 2016 107
Dormant Projects (Contd..1), H2 2016 108
Dormant Projects (Contd..2), H2 2016 109
Dormant Projects (Contd..3), H2 2016 110
Dormant Projects (Contd..4), H2 2016 111
Dormant Projects (Contd..5), H2 2016 112
Dormant Projects (Contd..6), H2 2016 113
Discontinued Products, H2 2016 114